Gilead defends investment in cell therapy manufacturing
Gilead’s continued investment in cell therapy manufacturing capabilities, at a time when sales at the nascent business unit are flatlining, was called into question by investors.
Archives for November 5, 2019
Astellas taps into Pandion’s platform for bispecifics development
Astellas and Pandion join forces to develop treatments for autoimmune pancreatic diseases using the latter’s modular immune effector.